US1920051067 - Common Stock
CODEXIS INC
NASDAQ:CDXS (5/3/2024, 7:00:02 PM)
After market: 3.95 +0.03 (+0.77%)3.92
+0.58 (+17.37%)
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 248 full-time employees. The company went IPO on 2010-04-22. The firm is engaged in discovering, developing and selling enzymes and other proteins. The firm commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. The company operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.
CODEXIS INC
200 Penobscot Dr
Redwood City CALIFORNIA 94063
P: 16504218100
CEO: John J. Nicols
Employees: 248
Website: https://www.codexis.com/
CDXS stock results show that Codexis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Codexis (NASDAQ:CDXS) just reported results for the first quarter of 2024.Codex...
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA...
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will...
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform...
Here you can normally see the latest stock twits on CDXS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: